关键数据
80.000今开
84.700最高
8.64M成交量
35.12市盈率 TTM
27.34市盈率动
--股息TTM
2.24%换手率
74.540昨收
79.665最低
480.60M成交额
56.25市盈率静
10.96市净率
0.00%股息率 TTM
13.90%ROA
89.98052周最高
2.12量比
576.20M净利润
385.90M总股本
2.3918每股收益TTM
1.44Beta
35.62%ROE
54.11052周最低
6.75%振幅
62.95%毛利率
32.41B总市值
3.66回报/风险
2.25%风险率
操作建议
Dexcom Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名15/199位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价86.50。中期看,股价处于上升通道。近一个月,市场表现一般,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
Dexcom Inc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Zimmer Biomet Holdings Inc
ZBH
31
Medline Ord Shs Class A
MDLN
29
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
Dexcom Inc简介
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
公司代码DXCM
公司Dexcom Inc
CEOMr. Jacob Steven (Jake) Leach
网址https://www.dexcom.com/
公司股东
常见问题
Dexcom Inc(DXCM)的当前股价是多少?
Dexcom Inc(DXCM)的当前股价是 74.57。
Dexcom Inc股票的52周最高点是89.98。
Dexcom Inc股票的52周最低点是54.11。
现在Dexcom Inc(DXCM)的股票是买入、持有还是卖出?
根据分析师评级,Dexcom Inc(DXCM)的总体评级为买入,目标价格为86.50。
Dexcom Inc(DXCM)股票的每股收益(EPS TTM)是多少
Dexcom Inc(DXCM)股票的每股收益(EPS TTM)是2.14。